[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.190.122. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
April 25, 2012

2008 US Preventive Services Task Force Recommendations and Prostate Cancer Screening Rates

Author Affiliations

Author Affiliations: Section of Urology (Drs Prasad and Eggener and Mr Drazer) (seggener@surgery.bsd.uchicago.edu), Department of Health Studies (Dr Huo), University of Chicago Medical Center, Chicago, Illinois; and Department of Urology, University of California, Los Angeles (Dr Hu).

JAMA. 2012;307(16):1692-1694. doi:10.1001/jama.2012.534

To the Editor: The US Preventive Services Task Force (USPSTF) recently drafted a grade D recommendation against prostate-specific antigen (PSA)–based screening for prostate cancer.1 If this recommendation becomes final, how it will affect clinical practice remains unclear. In 2008, the USPSTF issued a grade D recommendation against PSA-based screening in men aged 75 years or older.2 We evaluated changes in national screening rates before and after this recommendation.

According to federal regulations, the study was exempt from review by an institutional review board; patient data were deidentified and requirement for consent to our study was waived. Demographic, socioeconomic, and functional variables were collected from the 2005 and 2010 National Health Interview Survey (NHIS), which is a cross-sectional, in-person household survey continuously performed throughout each year on approximately 87 500 individuals (90% response rate).3 Multistage area probability sampling provides a representative sample of the US population. The Cancer Control Supplement, which contains questions regarding cancer screening, is included every 5 years.

×